{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:14:01Z","timestamp":1793319241716,"version":"4.5.0"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["8247103186, 82272704"],"award-info":[{"award-number":["8247103186, 82272704"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["92159301, 82425044, 82441028, 82473216, 82272704, 82341003, and 82072921"],"award-info":[{"award-number":["92159301, 82425044, 82441028, 82473216, 82272704, 82341003, and 82072921"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["92159301, 82425044, 82441028, 82473216, 82272704, 82341003, and 82072921"],"award-info":[{"award-number":["92159301, 82425044, 82441028, 82473216, 82272704, 82341003, and 82072921"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82441028"],"award-info":[{"award-number":["82441028"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Neoadjuvant dual HER2 blockade with trastuzumab and pertuzumab plus chemotherapy represents the current standard-of-care for HER2-positive breast cancer. However, treatment responses remain heterogeneous, underscoring the lack of clinically practical tools for predicting treatment efficacy and informing personalized therapy. Here, we developed HER2-LADDER (Layered AI-based Dual-targeteD anti-HER2 Recommendation), a spatially interpretable and clinically accessible artificial intelligence framework that integrates clinicopathological and spatial topological features from routine hematoxylin and eosin (H&amp;E) and HER2 immunohistochemistry (IHC) slides. Using these spatially derived features, HER2-LADDER accurately predicted response to neoadjuvant TCbHP\/PCbHP, achieving AUCs of 0.944 in the model construction cohort (\n                    <jats:italic>N<\/jats:italic>\n                    \u2009=\u2009276), 0.917 in the temporal validation cohort (\n                    <jats:italic>N<\/jats:italic>\n                    \u2009=\u200982), and 0.869 in the trial-based validation cohort (\n                    <jats:italic>N<\/jats:italic>\n                    \u2009=\u200985). On the basis of HER2-LADDER scores, patients were stratified into Low (highly responsive), Medium (responsive), and High (resistant) groups, identifying candidates for treatment de-escalation (THP or TCbH\/PCbH), standard-of-care (TCbHP\/PCbHP), or alternative regimens (e.g., next-generation anti-HER2 antibody\u2010drug conjugates), respectively. Importantly, Xenium in situ profiling further revealed biological correlates underlying model predictions, including HER2-enriched tumor cell aggregation and neutrophil-helper T-cell interactions, thereby highlighting the mechanistic interpretability of the model. Collectively, HER2-LADDER unites digital pathology and high-resolution spatial profiling into a clinically accessible AI framework, offering a robust, transparent, and biologically grounded tool to tailor individualized HER2-targeted therapy optimization.\n                  <\/jats:p>","DOI":"10.1038\/s41392-026-02734-0","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T23:02:32Z","timestamp":1781823752000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Spatially interpretable artificial intelligence framework to tailored neoadjuvant dual HER2 blockade in HER2-positive breast cancer"],"prefix":"10.1038","volume":"11","author":[{"given":"Xiang-Rong","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shen","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Hua","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei-Jie","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Zheng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Wei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi-Yu","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-Ting","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning-Ning","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Zhi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-Jie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8103-0505","authenticated-orcid":false,"given":"Jiong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3699-2630","authenticated-orcid":false,"given":"Yi-Zhou","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7712-822X","authenticated-orcid":false,"given":"Wen-Tao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gen-Hong","family":"Di","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4503-148X","authenticated-orcid":false,"given":"Zhi-Ming","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-4890-6424","authenticated-orcid":false,"given":"Ding","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,19]]},"reference":[{"key":"2734_CR1","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.1016\/S0140-6736(16)32417-5","volume":"389","author":"S Loibl","year":"2017","unstructured":"Loibl, S. & Gianni, L. HER2-positive breast cancer. Lancet 389, 2415\u20132429 (2017).","journal-title":"Lancet"},{"key":"2734_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s44178-022-00007-8","volume":"1","author":"J Wu","year":"2022","unstructured":"Wu, J. et al. CACA guidelines for holistic integrative management of breast cancer. Holist. Integr. Oncol. 1, 7 (2022).","journal-title":"Holist. Integr. Oncol."},{"key":"2734_CR3","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1126\/science.3798106","volume":"235","author":"DJ Slamon","year":"1987","unstructured":"Slamon, D. J. et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene. Science 235, 177\u2013182 (1987).","journal-title":"Science"},{"key":"2734_CR4","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41573-022-00579-0","volume":"22","author":"SM Swain","year":"2023","unstructured":"Swain, S. M., Shastry, M. & Hamilton, E. Targeting HER2-positive breast cancer: advances and future directions. Nat. Rev. Drug Discov. 22, 101\u2013126 (2023).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2734_CR5","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.annonc.2025.12.002","volume":"37","author":"G Gentile","year":"2025","unstructured":"Gentile, G., Gerosa, R., de Azambuja, E. & Piccart-Gebhart, M. 20th anniversary of adjuvant trastuzumab: reflections on a breakthrough moment. Ann. Oncol. 37, 470\u2013480 (2025).","journal-title":"Ann. Oncol."},{"key":"2734_CR6","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/S0140-6736(16)32616-2","volume":"389","author":"D Cameron","year":"2017","unstructured":"Cameron, D. et al. 11 years\u2019 follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin adjuvant (HERA) trial. Lancet 389, 1195\u20131205 (2017).","journal-title":"Lancet"},{"key":"2734_CR7","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0910383","volume":"365","author":"D Slamon","year":"2011","unstructured":"Slamon, D. et al. Adjuvant trastuzumab in HER2-positive breast cancer. N. Engl. J. Med. 365, 1273\u20131283 (2011).","journal-title":"N. Engl. J. Med."},{"key":"2734_CR8","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/S0140-6736(09)61964-4","volume":"375","author":"L Gianni","year":"2010","unstructured":"Gianni, L. et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 375, 377\u2013384 (2010).","journal-title":"Lancet"},{"key":"2734_CR9","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(11)70336-9","volume":"13","author":"L Gianni","year":"2012","unstructured":"Gianni, L. et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 13, 25\u201332 (2012).","journal-title":"Lancet Oncol."},{"key":"2734_CR10","doi-asserted-by":"publisher","first-page":"e193692","DOI":"10.1001\/jamaoncol.2019.3692","volume":"6","author":"Z Shao","year":"2020","unstructured":"Shao, Z. et al. Efficacy, safety, and tolerability of pertuzumab, trastuzumab, and docetaxel for patients with early or locally advanced ERBB2-positive breast cancer in Asia: the PEONY phase 3 randomized clinical trial. JAMA Oncol. 6, e193692 (2020).","journal-title":"JAMA Oncol."},{"key":"2734_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-45591-7","volume":"15","author":"L Huang","year":"2024","unstructured":"Huang, L. et al. Neoadjuvant-adjuvant pertuzumab in HER2-positive early breast cancer: final analysis of the randomized phase III PEONY trial. Nat. Commun. 15, 2153 (2024).","journal-title":"Nat. Commun."},{"key":"2734_CR12","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1093\/annonc\/mdt182","volume":"24","author":"A Schneeweiss","year":"2013","unstructured":"Schneeweiss, A. et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann. Oncol. 24, 2278\u20132284 (2013).","journal-title":"Ann. Oncol."},{"key":"2734_CR13","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1016\/S1470-2045(18)30570-9","volume":"19","author":"MS van Ramshorst","year":"2018","unstructured":"van Ramshorst, M. S. et al. Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 19, 1630\u20131640 (2018).","journal-title":"Lancet Oncol."},{"key":"2734_CR14","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1038\/s41571-024-00939-2","volume":"21","author":"AG Waks","year":"2024","unstructured":"Waks, A. G. et al. Dual HER2 inhibition: mechanisms of synergy, patient selection, and resistance. Nat. Rev. Clin. Oncol. 21, 818\u2013832 (2024).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2734_CR15","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/s41416-025-03287-9","volume":"134","author":"J Ma","year":"2025","unstructured":"Ma, J. et al. Spatial molecular analyses reveal key features associated with response to KN026 in advanced HER2-positive breast cancer. Br. J. Cancer 134, 685\u2013696 (2025).","journal-title":"Br. J. Cancer"},{"key":"2734_CR16","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S1470-2045(24)00581-3","volume":"26","author":"X-C Chen","year":"2025","unstructured":"Chen, X.-C. et al. De-escalated neoadjuvant weekly nab-paclitaxel with trastuzumab and pertuzumab versus docetaxel, carboplatin, trastuzumab, and pertuzumab in patients with HER2-positive early breast cancer (HELEN-006): a multicentre, randomised, phase 3 trial. Lancet Oncol. 26, 27\u201336 (2025).","journal-title":"Lancet Oncol."},{"key":"2734_CR17","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1016\/S1470-2045(21)00122-4","volume":"22","author":"JM P\u00e9rez-Garc\u00eda","year":"2021","unstructured":"P\u00e9rez-Garc\u00eda, J. M. et al. Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial. Lancet Oncol. 22, 858\u2013871 (2021).","journal-title":"Lancet Oncol."},{"key":"2734_CR18","doi-asserted-by":"publisher","first-page":"LBA500","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA500","volume":"43","author":"H-F Gao","year":"2025","unstructured":"Gao, H.-F. et al. De-escalated neoadjuvant taxane plus trastuzumab and pertuzumab with or without carboplatin in HER2-positive early breast cancer (neoCARHP): a multicentre, open-label, randomised, phase 3 trial. J. Clin. Oncol. 43, LBA500\u2013LBA500 (2025).","journal-title":"J. Clin. Oncol."},{"key":"2734_CR19","doi-asserted-by":"crossref","unstructured":"Li, J. J. et al. Efficacy and safety of neoadjuvant SHR-A1811 with or without pyrotinib in women with locally advanced or early HER2-positive breast cancer: a randomized, open-label, phase 2 trial. Ann. Oncol. 36, 651\u2013659 (2025).","DOI":"10.1016\/j.annonc.2025.02.011"},{"key":"2734_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-022-02708-3","volume":"20","author":"J Wu","year":"2022","unstructured":"Wu, J. et al. Neoadjuvant pyrotinib, trastuzumab, and docetaxel for HER2-positive breast cancer (PHEDRA): a double-blind, randomized phase 3 trial. BMC Med. 20, 498 (2022).","journal-title":"BMC Med."},{"key":"2734_CR21","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1093\/oncolo\/oyac247","volume":"28","author":"EM Lander","year":"2023","unstructured":"Lander, E. M. et al. Using the HER2\/CEP17 FISH ratio to predict pathologic complete response following neoadjuvant anti-HER2 doublet therapy in HER2+ breast cancer. Oncologist 28, 123\u2013130 (2023).","journal-title":"Oncologist"},{"key":"2734_CR22","doi-asserted-by":"publisher","first-page":"842","DOI":"10.3390\/cancers16040842","volume":"16","author":"SJ Bae","year":"2024","unstructured":"Bae, S. J. et al. Predictive markers of treatment response to neoadjuvant systemic therapy with dual HER2-blockade. Cancers 16, 842 (2024).","journal-title":"Cancers"},{"key":"2734_CR23","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1093\/annonc\/mdx647","volume":"29","author":"P Nuciforo","year":"2018","unstructured":"Nuciforo, P. et al. A predictive model of pathologic response based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer treated with chemo-free dual HER2 blockade. Ann. Oncol. 29, 170\u2013177 (2018).","journal-title":"Ann. Oncol."},{"key":"2734_CR24","doi-asserted-by":"publisher","first-page":"4123","DOI":"10.1158\/1078-0432.CCR-24-0464","volume":"30","author":"A Llombart-Cussac","year":"2024","unstructured":"Llombart-Cussac, A. et al. HER2DX genomic assay in HER2-positive early breast cancer treated with trastuzumab and pertuzumab: a correlative analysis from the PHERGain phase II trial. Clin. Cancer Res. 30, 4123\u20134130 (2024).","journal-title":"Clin. Cancer Res."},{"key":"2734_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.104320","volume":"85","author":"V Guarneri","year":"2022","unstructured":"Guarneri, V. et al. HER2DX genomic test in HER2-positive\/hormone receptor-positive breast cancer treated with neoadjuvant trastuzumab and pertuzumab: A correlative analysis from the PerELISA trial. EBioMedicine 85, 104320 (2022).","journal-title":"EBioMedicine"},{"key":"2734_CR26","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1001\/jamaoncol.2023.0187","volume":"9","author":"C Bueno-Mui\u00f1o","year":"2023","unstructured":"Bueno-Mui\u00f1o, C. et al. Assessment of a genomic assay in patients with ERBB2-positive breast cancer following neoadjuvant trastuzumab-based chemotherapy with or without pertuzumab. JAMA Oncol. 9, 841\u2013846 (2023).","journal-title":"JAMA Oncol."},{"key":"2734_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2019.06.001","volume":"118","author":"S Di Cosimo","year":"2019","unstructured":"Di Cosimo, S. et al. The 41-gene classifier TRAR predicts response of HER2 positive breast cancer patients in the NeoALTTO study. Eur. J. Cancer 118, 1\u20139 (2019).","journal-title":"Eur. J. Cancer"},{"key":"2734_CR28","doi-asserted-by":"publisher","first-page":"3887","DOI":"10.1158\/1078-0432.CCR-18-2507","volume":"25","author":"S Di Cosimo","year":"2019","unstructured":"Di Cosimo, S. et al. Plasma miRNA levels for predicting therapeutic response to neoadjuvant treatment in HER2-positive breast cancer: results from the NeoALTTO trial. Clin. Cancer Res. 25, 3887\u20133895 (2019).","journal-title":"Clin. Cancer Res."},{"key":"2734_CR29","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1038\/s41571-024-00926-7","volume":"21","author":"J Chen","year":"2024","unstructured":"Chen, J., Larsson, L., Swarbrick, A. & Lundeberg, J. Spatial landscapes of cancers: insights and opportunities. Nat. Rev. Clin. Oncol. 21, 660\u2013674 (2024).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2734_CR30","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/s41571-019-0299-9","volume":"17","author":"K Goutsouliak","year":"2020","unstructured":"Goutsouliak, K. et al. Towards personalized treatment for early stage HER2-positive breast cancer. Nat. Rev. Clin. Oncol. 17, 233\u2013250 (2020).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2734_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-42504-y","volume":"14","author":"S Zhao","year":"2023","unstructured":"Zhao, S. et al. Single-cell morphological and topological atlas reveals the ecosystem diversity of human breast cancer. Nat. Commun. 14, 6796 (2023).","journal-title":"Nat. Commun."},{"key":"2734_CR32","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/S1470-2045(25)00727-2","volume":"27","author":"G Shamai","year":"2026","unstructured":"Shamai, G. et al. Deep learning on histopathological images to predict breast cancer recurrence risk and chemotherapy benefit: a multicentre, model development and validation study. Lancet Oncol. 27, 512\u2013526 (2026).","journal-title":"Lancet Oncol."},{"key":"2734_CR33","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/j.ccell.2025.03.017","volume":"43","author":"D Ma","year":"2025","unstructured":"Ma, D. et al. Spatial determinants of antibody-drug conjugate SHR-A1811 efficacy in neoadjuvant treatment for HER2-positive breast cancer. Cancer Cell 43, 1061\u20131075.e7 (2025).","journal-title":"Cancer Cell"},{"key":"2734_CR34","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1056\/NEJMoa1413513","volume":"372","author":"SM Swain","year":"2015","unstructured":"Swain, S. M. et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N. Engl. J. Med. 372, 724\u2013734 (2015).","journal-title":"N. Engl. J. Med."},{"key":"2734_CR35","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/S1470-2045(16)00163-7","volume":"17","author":"L Gianni","year":"2016","unstructured":"Gianni, L. et al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. Lancet Oncol. 17, 791\u2013800 (2016).","journal-title":"Lancet Oncol."},{"key":"2734_CR36","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1016\/j.annonc.2023.05.012","volume":"34","author":"G Villacampa","year":"2023","unstructured":"Villacampa, G. et al. Association of HER2DX with pathological complete response and survival outcomes in HER2-positive breast cancer. Ann. Oncol. 34, 783\u2013795 (2023).","journal-title":"Ann. Oncol."},{"key":"2734_CR37","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1001\/jamaoncol.2023.0181","volume":"9","author":"AG Waks","year":"2023","unstructured":"Waks, A. G. et al. Assessment of the HER2DX assay in patients with ERBB2-positive breast cancer treated with neoadjuvant paclitaxel, trastuzumab, and pertuzumab. JAMA Oncol. 9, 835\u2013840 (2023).","journal-title":"JAMA Oncol."},{"key":"2734_CR38","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1016\/S1470-2045(20)30450-2","volume":"21","author":"A Prat","year":"2020","unstructured":"Prat, A. et al. A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation. Lancet Oncol. 21, 1455\u20131464 (2020).","journal-title":"Lancet Oncol."},{"key":"2734_CR39","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adr1576","volume":"11","author":"N Mao","year":"2025","unstructured":"Mao, N. et al. A multimodal and fully automated system for prediction of pathological complete response to neoadjuvant chemotherapy in breast cancer. Sci. Adv. 11, eadr1576 (2025).","journal-title":"Sci. Adv."},{"key":"2734_CR40","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s11547-025-01958-4","volume":"130","author":"L Urso","year":"2025","unstructured":"Urso, L. et al. 18F-FDG PET\/CT radiomic analysis and artificial intelligence to predict pathological complete response after neoadjuvant chemotherapy in breast cancer patients. Radio. Med. 130, 543\u2013554 (2025).","journal-title":"Radio. Med."},{"key":"2734_CR41","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/S1470-2045(22)00159-0","volume":"23","author":"U Nitz","year":"2022","unstructured":"Nitz, U. et al. De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+\/HR-): survival outcomes from a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol. 23, 625\u2013635 (2022).","journal-title":"Lancet Oncol."},{"key":"2734_CR42","doi-asserted-by":"publisher","first-page":"3478","DOI":"10.3390\/cancers16203478","volume":"16","author":"H Abdel-Razeq","year":"2024","unstructured":"Abdel-Razeq, H. De-escalating treatment strategies for patients with human epidermal growth factor receptor-2 (HER2)-positive early-stage breast cancer. Cancers 16, 3478 (2024).","journal-title":"Cancers"},{"key":"2734_CR43","first-page":"355","volume":"70","author":"GM Choong","year":"2020","unstructured":"Choong, G. M., Cullen, G. D. & O\u2019Sullivan, C. C. Evolving standards of care and new challenges in the management of HER2-positive breast cancer. CA Cancer J. Clin. 70, 355\u2013374 (2020).","journal-title":"CA Cancer J. Clin."},{"key":"2734_CR44","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.breast.2021.07.019","volume":"59","author":"F Schettini","year":"2021","unstructured":"Schettini, F. & Prat, A. Dissecting the biological heterogeneity of HER2-positive breast cancer. Breast 59, 339\u2013350 (2021).","journal-title":"Breast"},{"key":"2734_CR45","doi-asserted-by":"publisher","first-page":"e176454","DOI":"10.1172\/JCI176454","volume":"134","author":"Z Li","year":"2024","unstructured":"Li, Z. et al. HER2 heterogeneity and treatment response-associated profiles in HER2-positive breast cancer in the NCT02326974 clinical trial. J. Clin. Invest. 134, e176454 (2024).","journal-title":"J. Clin. Invest."},{"key":"2734_CR46","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1038\/s41591-023-02478-2","volume":"29","author":"F Mosele","year":"2023","unstructured":"Mosele, F. et al. Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial. Nat. Med. 29, 2110\u20132120 (2023).","journal-title":"Nat. Med."},{"key":"2734_CR47","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.trecan.2023.11.001","volume":"10","author":"C Valenza","year":"2024","unstructured":"Valenza, C. et al. Targeting HER2 heterogeneity in breast and gastrointestinal cancers. Trends Cancer 10, 113\u2013123 (2024).","journal-title":"Trends Cancer"},{"key":"2734_CR48","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1111\/cas.12966","volume":"107","author":"Y Ogitani","year":"2016","unstructured":"Ogitani, Y., Hagihara, K., Oitate, M., Naito, H. & Agatsuma, T. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. Cancer Sci. 107, 1039\u20131046 (2016).","journal-title":"Cancer Sci."},{"key":"2734_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-58266-8","volume":"16","author":"L-C Tsao","year":"2025","unstructured":"Tsao, L.-C. et al. Effective extracellular payload release and immunomodulatory interactions govern the therapeutic effect of trastuzumab deruxtecan (T-DXd). Nat. Commun. 16, 3167 (2025).","journal-title":"Nat. Commun."},{"key":"2734_CR50","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-076065","volume":"383","author":"F Ma","year":"2023","unstructured":"Ma, F. et al. Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): randomised, double blind, multicentre, phase 3 trial. BMJ 383, e076065 (2023).","journal-title":"BMJ"},{"key":"2734_CR51","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abn3966","volume":"8","author":"X Wang","year":"2022","unstructured":"Wang, X. et al. Spatial interplay patterns of cancer nuclei and tumor-infiltrating lymphocytes (TILs) predict clinical benefit for immune checkpoint inhibitors. Sci. Adv. 8, eabn3966 (2022).","journal-title":"Sci. Adv."},{"key":"2734_CR52","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1038\/s43018-021-00190-z","volume":"2","author":"KL McNamara","year":"2021","unstructured":"McNamara, K. L. et al. Spatial proteomic characterization of HER2-positive breast tumors through neoadjuvant therapy predicts response. Nat. Cancer 2, 400\u2013413 (2021).","journal-title":"Nat. Cancer"},{"key":"2734_CR53","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1182\/blood-2016-10-744441","volume":"129","author":"M Vono","year":"2017","unstructured":"Vono, M. et al. Neutrophils acquire the capacity for antigen presentation to memory CD4+ T cells in vitro and ex vivo. Blood 129, 1991\u20132001 (2017).","journal-title":"Blood"},{"key":"2734_CR54","doi-asserted-by":"publisher","first-page":"4128","DOI":"10.1182\/blood.V89.11.4128","volume":"89","author":"NA Fanger","year":"1997","unstructured":"Fanger, N. A. et al. Activation of human T cells by major histocompatability complex class II expressing neutrophils: proliferation in the presence of superantigen, but not tetanus toxoid. Blood 89, 4128\u20134135 (1997).","journal-title":"Blood"},{"key":"2734_CR55","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1016\/j.ccell.2024.08.008","volume":"42","author":"M Lad","year":"2024","unstructured":"Lad, M. et al. Glioblastoma induces the recruitment and differentiation of dendritic-like \u201chybrid\u201d neutrophils from skull bone marrow. Cancer Cell 42, 1549\u20131569.e16 (2024).","journal-title":"Cancer Cell"},{"key":"2734_CR56","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1016\/j.cell.2024.02.005","volume":"187","author":"Y Wu","year":"2024","unstructured":"Wu, Y. et al. Neutrophil profiling illuminates anti-tumor antigen-presenting potency. Cell 187, 1422\u20131439.e24 (2024).","journal-title":"Cell"},{"key":"2734_CR57","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-014-0241-z","volume":"13","author":"GS Collins","year":"2015","unstructured":"Collins, G. S., Reitsma, J. B., Altman, D. G. & Moons, K. G. M. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. BMC Med. 13, 1 (2015).","journal-title":"BMC Med."},{"key":"2734_CR58","doi-asserted-by":"publisher","first-page":"3867","DOI":"10.1200\/JCO.22.02864","volume":"41","author":"AC Wolff","year":"2023","unstructured":"Wolff, A. C. et al. Human epidermal growth factor receptor 2 testing in breast cancer: ASCO-College of American Pathologists Guideline Update. J. Clin. Oncol. 41, 3867\u20133872 (2023).","journal-title":"J. Clin. Oncol."},{"key":"2734_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/j.media.2019.101563","volume":"58","author":"S Graham","year":"2019","unstructured":"Graham, S. et al. Hover-Net: simultaneous segmentation and classification of nuclei in multi-tissue histology images. Med. Image Anal. 58, 101563 (2019).","journal-title":"Med. Image Anal."},{"key":"2734_CR60","doi-asserted-by":"crossref","unstructured":"Gamper, J., Alemi Koohbanani, N., Benet, K., Khuram, A. & Rajpoot, N. PanNuke: An Open Pan-Cancer Histology Dataset for Nuclei Instance Segmentation and Classification (Springer International Publishing, 2019).","DOI":"10.1007\/978-3-030-23937-4_2"},{"key":"2734_CR61","doi-asserted-by":"publisher","first-page":"3413","DOI":"10.1109\/TMI.2021.3085712","volume":"40","author":"R Verma","year":"2021","unstructured":"Verma, R. et al. MoNuSAC2020: a multi-organ nuclei segmentation and classification challenge. IEEE Trans. Med. Imaging 40, 3413\u20133423 (2021).","journal-title":"IEEE Trans. Med. Imaging"},{"key":"2734_CR62","doi-asserted-by":"crossref","unstructured":"Li, H. et al. Segment Membranes and Nuclei from Histopathological Images via Nuclei Point-Level Supervision. In Medical Image Computing and Computer Assisted Intervention \u2013 MICCAI 2023 (eds. Greenspan, H., et al.) 539\u2013548 (Springer Nature, 2023).","DOI":"10.1007\/978-3-031-43987-2_52"},{"key":"2734_CR63","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/S0140-6736(11)61941-7","volume":"379","author":"JR Kratz","year":"2012","unstructured":"Kratz, J. R. et al. A practical molecular assay to predict survival in resected non-squamous, non-small-cell lung cancer: development and international validation studies. Lancet 379, 823\u2013832 (2012).","journal-title":"Lancet"},{"key":"2734_CR64","doi-asserted-by":"publisher","first-page":"e078378","DOI":"10.1136\/bmj-2023-078378","volume":"385","author":"GS Collins","year":"2024","unstructured":"Collins, G. S. et al. TRIPOD+AI statement: updated guidance for reporting clinical prediction models that use regression or machine learning methods. BMJ 385, e078378 (2024).","journal-title":"BMJ"},{"key":"2734_CR65","unstructured":"Lundberg, S. M. & Lee, S.-I. A unified approach to interpreting model predictions. In Proc. 31st International Conference on Neural Information Processing Systems 4768\u20134777 (Curran Associates Inc., 2017)"}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02734-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02734-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02734-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T23:02:34Z","timestamp":1781823754000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02734-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,19]]},"references-count":65,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2734"],"URL":"https:\/\/doi.org\/10.1038\/s41392-026-02734-0","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,19]]},"assertion":[{"value":"19 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"241"}}